Issue 7, 2014

Synthesis of isoxazole moiety containing ferrocene derivatives and preliminarily in vitro anticancer activity

Abstract

Seven new structures of an isoxazole moiety containing ferrocene derivatives (3a–3g) were firstly synthesized and characterized by 1H NMR, 13C NMR, ESI-MS. Subsequently, their in vitro anticancer activity against A549, HCT116 and MCF-7 cell lines was preliminarily evaluated using the MTT method. Among them, 3d exhibited a wide spectrum and the most potent anticancer activity against A549 and HCT116 cell lines (IC50s: 0.747 and 3.65 nM, respectively) as compared with the reference drug gefitinib (IC50s: 17.90 and 21.55 μM, respectively). 3d can be seen as the best candidate for development of anticancer drugs.

Graphical abstract: Synthesis of isoxazole moiety containing ferrocene derivatives and preliminarily in vitro anticancer activity

Article information

Article type
Concise Article
Submitted
02 Apr 2014
Accepted
21 May 2014
First published
22 May 2014

Med. Chem. Commun., 2014,5, 968-972

Synthesis of isoxazole moiety containing ferrocene derivatives and preliminarily in vitro anticancer activity

J. Yong, C. Lu and X. Wu, Med. Chem. Commun., 2014, 5, 968 DOI: 10.1039/C4MD00151F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements